Recent Advances in Noncoding RNA Modifications of Gastrointestinal Cancer

Overview

Journal Cancer Sci

Specialty Oncology

Date 2024 Nov 2

PMID 39487589

Authors

Tomoaki Hara

Sikun Meng

Yasuko Arao

Yoshiko Saito

Kana Inoue

Sarah Rennie

Ken Ofusa

Yuichiro Doki

Hidetoshi Eguchi

Toru Kitagawa

Hideshi Ishii

Affiliations

Soon will be listed here.

Abstract

Elucidating the mechanisms underlying cancer development and proliferation is important for the development of therapeutic methods for the complete cure of cancer. In particular, the identification of diagnostic markers for early detection and new therapeutic strategies for refractory gastrointestinal cancers are needed. Various abnormal phenomena occur in cancer cells, such as functional changes of proteins, led by genomic mutations, and changes in gene expression due to dysregulation of epigenetic regulation. This is no exception for noncoding RNA (ncRNA), which do not encode proteins. Recent reports have revealed that microRNA (miRNA), long noncoding RNA (lncRNA), and circular RNA (circRNA) are deeply involved in cancer progression. These ncRNAs have attracted attention as gene expression regulatory molecules. Recent advances in technology have made it possible not only to read DNA and RNA sequences but also to study the modification state of each base. In particular, comprehensive analysis of N6-methyladenosine (mA) has been performed by many research groups, with multiple studies reporting that mA modifications of specific genes are associated with cancer progression. Based on the above, this review examines how ncRNA modifications are related to cancer progression in gastrointestinal cancers such as colorectal and pancreatic cancer. We also discuss enzyme inhibitors that have been reported to have drug discovery potential targeting mA modifications. By utilizing the new perspective of ncRNA modification, we may be able to accumulate knowledge on the molecular biology of cancer and contribute to human health through diagnosis and treatment.

Citing Articles

Recent Exploration of Solid Cancer Biomarkers Hidden Within Urine or Blood Exosomes That Provide Fundamental Information for Future Cancer Diagnostics.

Hara T, Meng S, Alshammari A, Hatakeyama H, Arao Y, Saito Y Diagnostics (Basel). 2025; 15(5).

PMID: 40075875 PMC: 11899240. DOI: 10.3390/diagnostics15050628.

LUCAT1-Mediated Competing Endogenous RNA (ceRNA) Network in Triple-Negative Breast Cancer.

Verma D, Siddharth S, Yende A, Wu Q, Sharma D Cells. 2024; 13(22).

PMID: 39594666 PMC: 11593075. DOI: 10.3390/cells13221918.

Recent advances in noncoding RNA modifications of gastrointestinal cancer.

Hara T, Meng S, Arao Y, Saito Y, Inoue K, Rennie S Cancer Sci. 2024; 116(1):8-20.

PMID: 39487589 PMC: 11711047. DOI: 10.1111/cas.16380.

References

Tsuji Y, Hara T, Meng S, Sato H, Arao Y, Ofusa K . Role of RNA methylation in the regulation of pancreatic cancer stem cells (Review). Oncol Lett. 2023; 26(2):336. PMC: 10326658. DOI: 10.3892/ol.2023.13922. View

Huang Y, Zhang W, Li Q, Wang Z, Yang X . Identification of m6A/m5C/m1A-associated LncRNAs for prognostic assessment and immunotherapy in pancreatic cancer. Sci Rep. 2023; 13(1):3661. PMC: 9985641. DOI: 10.1038/s41598-023-30865-9. View

Lin C, Ma M, Zhang Y, Li L, Long F, Xie C . The N-methyladenosine modification of circALG1 promotes the metastasis of colorectal cancer mediated by the miR-342-5p/PGF signalling pathway. Mol Cancer. 2022; 21(1):80. PMC: 8933979. DOI: 10.1186/s12943-022-01560-6. View

Masrour M, Khanmohammadi S, Fallahtafti P, Hashemi S, Rezaei N . Long non-coding RNA as a potential diagnostic and prognostic biomarker in melanoma: A systematic review and meta-analysis. J Cell Mol Med. 2024; 28(3):e18109. PMC: 10844705. DOI: 10.1111/jcmm.18109. View

Liu Z, Zheng N, Li J, Li C, Zheng D, Jiang X . N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells. Drug Resist Updat. 2022; 65:100886. DOI: 10.1016/j.drup.2022.100886. View

Hao S, Sun H, Sun H, Zhang B, Ji K, Liu P . STM2457 Inhibits the Invasion and Metastasis of Pancreatic Cancer by Down-Regulating BRAF-Activated Noncoding RNA N6-Methyladenosine Modification. Curr Issues Mol Biol. 2023; 45(11):8852-8863. PMC: 10670688. DOI: 10.3390/cimb45110555. View

Zhang J, Guo S, Piao H, Wang Y, Wu Y, Meng X . ALKBH5 promotes invasion and metastasis of gastric cancer by decreasing methylation of the lncRNA NEAT1. J Physiol Biochem. 2019; 75(3):379-389. PMC: 6728298. DOI: 10.1007/s13105-019-00690-8. View

Huff S, Kummetha I, Zhang L, Wang L, Bray W, Yin J . Rational Design and Optimization of mA-RNA Demethylase FTO Inhibitors as Anticancer Agents. J Med Chem. 2022; 65(16):10920-10937. PMC: 9421652. DOI: 10.1021/acs.jmedchem.1c02075. View

Chen J, Tao Y, Hong Y, Li H, Huang Z, Xu X . MA-mediated up-regulation of LncRNA LIFR-AS1 enhances the progression of pancreatic cancer via miRNA-150-5p/ VEGFA/Akt signaling. Cell Cycle. 2021; 20(23):2507-2518. PMC: 8794522. DOI: 10.1080/15384101.2021.1991122. View

10.

You Y, Fu Y, Huang M, Shen D, Zhao B, Liu H . Recent Advances of m6A Demethylases Inhibitors and Their Biological Functions in Human Diseases. Int J Mol Sci. 2022; 23(10). PMC: 9144293. DOI: 10.3390/ijms23105815. View

11.

Wang X, Guan D, Wang D, Liu H, Wu Y, Gong W . Genetic variants in mA regulators are associated with gastric cancer risk. Arch Toxicol. 2021; 95(3):1081-1088. DOI: 10.1007/s00204-020-02958-1. View

12.

Hara T, Meng S, Tsuji Y, Arao Y, Saito Y, Sato H . RN7SL1 may be translated under oncogenic conditions. Proc Natl Acad Sci U S A. 2024; 121(12):e2312322121. PMC: 10962956. DOI: 10.1073/pnas.2312322121. View

13.

Sun Y, Li S, Yu W, Zhao Z, Gao J, Chen C . N-methyladenosine-dependent pri-miR-17-92 maturation suppresses PTEN/TMEM127 and promotes sensitivity to everolimus in gastric cancer. Cell Death Dis. 2020; 11(10):836. PMC: 7547657. DOI: 10.1038/s41419-020-03049-w. View

14.

Qin B, Bai Q, Yan D, Yin F, Zhu Z, Xia C . Discovery of novel mRNA demethylase FTO inhibitors against esophageal cancer. J Enzyme Inhib Med Chem. 2022; 37(1):1995-2003. PMC: 9291647. DOI: 10.1080/14756366.2022.2098954. View

15.

Lin C, Wang Y, Dong Y, Lai S, Wang L, Weng S . N6-methyladenosine-mediated SH3BP5-AS1 upregulation promotes GEM chemoresistance in pancreatic cancer by activating the Wnt signaling pathway. Biol Direct. 2022; 17(1):33. PMC: 9673340. DOI: 10.1186/s13062-022-00347-5. View

16.

Yuan H, Liu J, Zhao L, Wu P, Chen G, Chen Q . Prognostic Risk Model and Tumor Immune Environment Modulation of m5C-Related LncRNAs in Pancreatic Ductal Adenocarcinoma. Front Immunol. 2021; 12:800268. PMC: 8692582. DOI: 10.3389/fimmu.2021.800268. View

17.

Wang Y, Zhu G, Tian D, Zhou C, Li N, Feng Y . Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer. BMC Cancer. 2022; 22(1):316. PMC: 8943990. DOI: 10.1186/s12885-022-09377-8. View

18.

Chen K, Zhang J, Meng L, Kong L, Lu M, Wang Z . The epigenetic downregulation of LncGHRLOS mediated by RNA m6A methylase ZCCHC4 promotes colorectal cancer tumorigenesis. J Exp Clin Cancer Res. 2024; 43(1):44. PMC: 10848513. DOI: 10.1186/s13046-024-02965-5. View

19.

Chen B, Hong Y, Gui R, Zheng H, Tian S, Zhai X . N6-methyladenosine modification of circ_0003215 suppresses the pentose phosphate pathway and malignancy of colorectal cancer through the miR-663b/DLG4/G6PD axis. Cell Death Dis. 2022; 13(9):804. PMC: 9489788. DOI: 10.1038/s41419-022-05245-2. View

20.

Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G . Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021; 593(7860):597-601. PMC: 7613134. DOI: 10.1038/s41586-021-03536-w. View